Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Vivus, Qnexa, Arena, Lorcaserin and the FDA | Main | Biosimilars: Not Easy, But Not Impossible, Either »

July 23, 2010

Aventis: Is It Genzyme?

Email This Entry

Posted by Derek

Genzyme's stock has jumped straight up this afternoon, and word is that they're the target of the rumored Sanofi-Aventis takeover move. This is being attributed to "people with knowledge of the matter", which is generally shorthand for "people that we know are highly placed insiders but that we've agreed not to name".

You have to think that if GENZ hadn't had their manufacturing woes that this wouldn't be happening.

Comments (10) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. Anonymous on July 23, 2010 10:27 PM writes...

I heard there was a recent ca. 50% reduction in their chemistry staff at the Bridgewater site. Anyone heard anything?

Permalink to Comment

2. Anonymous on July 23, 2010 10:40 PM writes...

Sanofi Aventis Bridgewater NJ site that is!

Permalink to Comment

3. Anonymous on July 23, 2010 10:41 PM writes...

Sanofi Aventis Bridgewater NJ site that is!

Permalink to Comment

4. petros on July 24, 2010 2:20 AM writes...

Further support of such moves from the FT
http://www.ft.com/cms/s/0/7ba187b4-96b1-11df-9caa-00144feab49a.html

Permalink to Comment

5. Watcher on July 24, 2010 9:22 AM writes...

In the way of business cycles, traditional Pharma has run the course of being at the top of its game, and now finds itself in a decade or more of downward adjustment. There will have to be more downsizing, job losses and continued consolidations as major players feel obligated to fiddle and rework the business models.

Nothing will substitute for innovative, profitable new drugs, where the numbers are becoming year by year. In the end, big money will increasingly chase those increasingly smaller number of new entities.

Permalink to Comment

6. MLBpitcher_and_MedicinalChemist on July 24, 2010 2:05 PM writes...

Tough game against the Marlins, yesterday Derek! At least you weren't credited with a loss, just a no-decision cause Wagner was unable to close the game.

Permalink to Comment

7. Mike G on July 24, 2010 6:54 PM writes...

#5, Pharma is betting that biogenerics and emerging markets will go a long way to substituting for innovative drugs. In the decades it will take for those initiatives to run their course, maybe Pharma will get its innovation mojo back?

Permalink to Comment

8. MLBpitcher_and_MedicinalChemist on July 24, 2010 8:25 PM writes...

@Mike G.

I guess it depends on the barriers to entry for biogenerics. It is obvious that they are higher than small molecule pharmaceuticals, so it will favor companies that already have the infrastructure for manufacturing biogenerics and have the liquidity to fund the trials.

-----

Derek should also talk about baseball instead of just the phrama industry. Pretty unusual that a blog run by an MLB pitcher doesn't even mention baseball.

Permalink to Comment

9. eurail pass on July 25, 2010 8:16 PM writes...

Doesn't surprise me one bit.

Permalink to Comment

10. David P on July 26, 2010 3:06 PM writes...

The word I got from PharmaGossip is that Sanofi's offer was rebuffed by Genzyme.

(Reuters) - Biotechnology company Genzyme Corp (GENZ.O) has rebuffed a takeover approach by France's Sanofi-Aventis (SASY.PA), Bloomberg reported on Monday, citing two people with knowledge of the matter.

Shares of Genzyme, which specializes in expensive medicines for rare genetic disorders, rose more than 8 percent to their highest level since February 2009. Such a rejection could signal the U.S. company will hold firm unless it receives a higher offer from Sanofi or another drugmaker.

Sanofi and Genzyme declined to comment on the reported rebuff.

Sources told Reuters on Friday that Sanofi had approached Genzyme two weeks earlier with an informal bid to buy the company and was awaiting a response. On the same day, Sanofi cut its earnings outlook for the year after U.S. regulators approved a generic version of blood thinner Lovenox, Sanofi's No. 2 product.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .